Molecular biology
Rising cell-free DNA level tracks cancer-associated methylation signal and improves multicancer detection
Summary
Analyzing 1,480 untreated participants across 43 hospitals, this study challenges the assumption that elevated total circulating cell-free DNA (ccfDNA) merely dilutes tumor-derived DNA through immune-derived shedding. Instead, rising total ccfDNA levels are correlated with an enrichment of cancer-associated DNA methylation signals, independent of cancer type, clinical stage, or technical covariates. In fact, ccfDNA concentration explains more variance in methylation signal than cancer stage itself. Clinically, higher ccfDNA yields significantly increased multicancer detection sensitivity, rising from 0.55 in the lowest concentration tertile to 0.85 in the highest for stage I, and from 0.59 to 0.86 for stage II.
Critical appraisal
From a biomolecular perspective, this work revises the conceptual model of liquid biopsies by demonstrating that elevated circulating cell-free DNA (ccfDNA) is enriched in, rather than diluted of, cancer-associated methylation signatures. This indicates a mechanistic coupling between host immune cell turnover and tumor-associated epigenetic alterations, observed also in symptomatic benign growths. Analytically, ccfDNA concentration directly governs assay sensitivity in early-stage cancers, with stage I sensitivity shifting from 0.55 in the lowest ccfDNA tertile to 0.85 in the highest (and stage II from 0.59 to 0.86). Consequently, integrating total ccfDNA concentration as an independent stratification metric will be critical for standardizing, benchmarking, and optimizing future multicancer early detection (MCED) methylation-based diagnostic assays.
The summary and the appraisal were written by a language model from the title and abstract of the original article. The article was selected automatically by a model, without human review. Methodology